Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Change in Receivables (2016 - 2025)

Jaguar Health (JAGX) has disclosed Change in Receivables for 11 consecutive years, with -$103000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables fell 106.0% to -$103000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $188000.0, a 120.91% increase, with the full-year FY2024 number at -$440000.0, down 13.99% from a year prior.
  • Change in Receivables was -$103000.0 for Q3 2025 at Jaguar Health, down from $317000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.4 million in Q1 2021 to a low of -$2.9 million in Q4 2021.
  • A 5-year average of -$187842.1 and a median of -$103000.0 in 2025 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: surged 324.14% in 2021, then tumbled 1137.21% in 2023.
  • Jaguar Health's Change in Receivables stood at -$2.9 million in 2021, then skyrocketed by 94.25% to -$166000.0 in 2022, then fell by 9.04% to -$181000.0 in 2023, then skyrocketed by 253.59% to $278000.0 in 2024, then plummeted by 137.05% to -$103000.0 in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Change in Receivables are -$103000.0 (Q3 2025), $317000.0 (Q2 2025), and -$304000.0 (Q1 2025).